Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Non-Current Debt (2022 - 2024)

Spruce Biosciences (SPRB) has disclosed Non-Current Debt for 3 consecutive years, with $124000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Non-Current Debt fell 92.78% to $124000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $124000.0, a 92.78% decrease, with the full-year FY2024 number at $124000.0, down 92.78% from a year prior.
  • Non-Current Debt was $124000.0 for Q4 2024 at Spruce Biosciences, down from $524000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $4.5 million in Q1 2022 to a low of $124000.0 in Q4 2024.
  • A 3-year average of $2.3 million and a median of $2.3 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: crashed 35.32% in 2023, then plummeted 92.78% in 2024.
  • Spruce Biosciences' Non-Current Debt stood at $3.3 million in 2022, then crashed by 47.86% to $1.7 million in 2023, then tumbled by 92.78% to $124000.0 in 2024.
  • Per Business Quant, the three most recent readings for SPRB's Non-Current Debt are $124000.0 (Q4 2024), $524000.0 (Q3 2024), and $923000.0 (Q2 2024).